The effect of fosfomycin on nedaplatin-induced nephrotoxicity in rats

• Published in: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy Vol. 11; no. 1; pp. 14 - 17
• Main Authors: Yoshiyama, Yuji, Kanke, Motoko, Yamaguchi, Kazue, Matsuo, Kazuhiro, Kurokawa, Minoru
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.02.2005
• Subjects: Acetylglucosaminidase - urine; Animals; Blood Urea Nitrogen; Creatinine - blood; Disease Models, Animal; Fosfomycin; Fosfomycin - administration & dosage; Fosfomycin - pharmacology; Fosfomycin - therapeutic use; Injections, Intraperitoneal; Kidney Tubular Necrosis, Acute - chemically induced; Kidney Tubular Necrosis, Acute - drug therapy; Male; Nedaplatin; Nephrotoxicity; Organoplatinum Compounds; Random Allocation; Rats; Rats, Wistar; Nedaplatin; Rats; Nephrotoxicity; Fosfomycin
• ISSN: 1341-321X; 1437-7780
• DOI: 10.1007/s10156-004-0361-Z

The effect of coadministration of fosfomycin (FOM) on nedaplatin-induced nephrotoxicity in rats was investigated for 6 days. FOM decreased nedaplatin-induced nephrotoxicity, as shown by reduced blood urea nitrogen (BUN), serum creatinine levels, and urinary excretion of N-acetyl-β-d-glucosaminidase (NAG). Further, there were fewer histopathological signs of nephrotoxicity in the groups treated with the combination of nedaplatin and FOM as compared with the nedaplatin-alone group. The concentration of nedaplatin was significantly lower in the renal cortex of rats treated with the combination of nedaplatin and FOM as compared with those treated with nedaplatin alone (p<0.05). In conclusion, the concomitant administration of FOM and nedaplatin may help to achieve a chemotherapeutic strategy that reduces the nephrotoxic effects of nedaplatin.